Hemostemix - HMTXF STOCK NEWS

Hemostemix (HMTXF) has secured a perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, positioning itself as a leader in the global stem cell market. The company will pay CytoImmune $5,000,000 (twenty million shares) for the license, subject to TSXV Exchange acceptance.

The strategic advantages include achieving the lowest cost of goods sold for allogenic products, creating a protective barrier around autologous stem cell production, and enhancing ACP-01's scalability. The bioreactor technology offers automated cell expansion, high yield efficiency, reduced facility and labor costs, and economies of scale.

This acquisition enables Hemostemix to expand clinical trials, accelerate regulatory approvals, pursue strategic partnerships, and increase profitability through improved gross margins. The technology leverages CytoImmune's expertise in bioreactor design and AI integration for optimized cell production.

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) has issued a clarification regarding its February 10, 2025 announcement about engaging Proconsul Capital for investor relations services. The clarification comes at the request of the Canadian Investment Regulatory Organization (CIRO). The engagement, which began February 6, 2025, involves investor relations and market awareness services with compensation set at $6,000 per month on a month-to-month basis. No stock options have been granted initially, though negotiations for options may occur after three months. The arrangement is subject to TSX Venture Exchange acceptance, and Hemostemix confirms compliance with TSXV Policy 3.4 regarding investor relations activities.

Hemostemix PR Inc. congratulates Luis Muñoz Marín International Airport (SJU) on achieving IATA's CEIV Pharma Certification, a prestigious recognition that places the airport among elite global hubs like Miami and Amsterdam. This certification validates SJU's adherence to the highest standards in handling, storage, and transportation of biologics and pharmaceutical products.

The certification strengthens Puerto Rico's position as a global leader in biologics and pharmaceutical logistics, providing Hemostemix PR Inc. with access to a world-leading certified biologics logistics hub. This infrastructure advancement supports the company's mission by enabling efficient delivery of ACP-01 therapies to patients worldwide, ensuring sensitive biologics are transported with maximum care and compliance.

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced the engagement of ProConsul Capital to provide investment marketing consulting services, effective February 6th, 2025. The agreement includes a monthly fee of $6,000 and stock options to be granted to ProConsul, with details to be announced later. The contract operates on a month-to-month renewal basis and can be terminated by either party with 30 days written notice.

Hemostemix (TSXV: HEM) (OTC: HMTXF) announced that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at $0.295 per share, resulting in the issuance of 1,634,466 Common Shares. The transaction is subject to TSXV Exchange approval.

Following the Hemostemix technology transfer presentation at CytoImmune's Innovations & Investment Conference, CytoImmune plans to present Hemostemix's clinical trial results to various medical practitioners in Puerto Rico. The initiative aims to treat no-option patients under a special access program, demonstrate patient improvements, and track healthcare cost reductions. The company highlighted potential revenue opportunities for medical practitioners, stating that implementing four ACP-01 procedures daily could generate additional income of $1,000,000, with each treatment unit priced at $37,000.

Hemostemix (TSXV: HEM) (OTC: HMTXF) has announced its expansion into the Dominican Republic with its ACP-01 therapy. The company has partnered with a team of cardiologists capable of treating 110 patients monthly, who have previously treated 200 ACP-01 recipients. Each ACP unit is priced at USD $37,000.

The treatment's efficacy is documented in a study published in Stem Cell Research and Therapy, involving 54 subjects treated for ischemic and non-ischemic dilated cardiomyopathy. The results showed significant improvements in ejection fraction, with increases of up to 47.1% in dilated cardiomyopathy patients and up to 27% in ischemic cardiomyopathy patients with an ejection fraction of 20% or less.

Hemostemix (HMTXF) has announced its first sales orders for ACP-01 Treatments following a social media campaign and presentations in Puerto Rico. The company has secured initial signed commitments amounting to $400,000 for 2025, with 11 months of selling ahead.

The company's CEO, Thomas Smeenk, highlighted that advanced sales help patients understand their treatment sequence and enable efficient scheduling of physician time and production. During recent meetings with physicians who have treated approximately 200 patients with ACP-01, an invasive cardiologist emphasized the unique effectiveness of ACP-01 in rebuilding heart function, stating it outperforms other autologous stem cell products specifically for cardiac applications.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced its listing on the TradeGateExchange.De under symbol 2VF0, effective January 27, 2025. The company's management and directors have invested over $9.1 Million since 2020.

The company's product, ACP-01, has demonstrated safety across 498 treatments, with results documented in seven studies involving 318 subjects and nine peer-reviewed publications. The treatment shows efficacy in limb salvation, heart function regeneration, and mental acuity improvement.

The TradeGateExchange listing offers several benefits including extended trading hours, real-time market data, competitive fee structures, efficient order execution, and enhanced accessibility for European investors.

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) has announced its uplisting to the OTCQB market, commencing trading on January 23, 2025. The company's CEO, Thomas Smeenk, is presenting 'Welcome to Your Fountain of Youth!' at the Sequire Investor Summit.

Management and directors have invested over $9.1 Million in Hemostemix since 2020. The company's ACP-01 therapy has demonstrated success in saving limbs from amputation, regenerating heart function, and mental acuity, with safety proven across 498 treatments. These results are documented in seven studies involving 318 subjects and nine peer-reviewed publications.

The OTCQB listing is expected to bring multiple benefits including increased transparency, higher liquidity, broader investor access, enhanced market visibility, and improved corporate governance standards.